VG Med WF lungs lower lobes panlobular emphysema lower lobes and upper lobes centrilobular emphysema bronchial wall thickening alpha 1 antitrypsin deficiency CT 55 year old male dyspnea

1. Challenge

Ashley Davidoff MD

50M Smoker Dyspnea

5 Major Findings

2. Findings

Panlobular Emphysema Lower Lobes

Upper Lobes Centrilobular Emphysema

Architectural Distortion

Bronchial Wall Thickening

Panlobular Emphysema in Alpha-1 Antitrypsin Deficiency
Multiplanar CT of the chest, including axial (a), magnified axial (b), and coronal (c) views, demonstrates extensive and severe panlobular emphysematous changes. This is manifest as expanded, low-attenuation secondary lobules with a paucity of blood vessels, reflecting diffuse destruction of the lung parenchyma, which is most pronounced in the lower lobes. Associated findings include segmental airway thickening, flattening of the diaphragms indicating hyperinflation, and mild centrilobular emphysematous changes in the upper lobes.
The lower-lobe predominance of emphysema is the classic imaging hallmark of panlobular emphysema secondary to alpha-1 antitrypsin (A1AT) deficiency. This genetic disorder leads to the destruction of the alveolar walls, while the airway thickening is consistent with associated chronic bronchitis. The concurrent finding of mild upper-lobe centrilobular emphysema is related to the patient’s history of smoking, which significantly accelerates lung damage in individuals with A1AT deficiency
Lower-lobe predominant panlobular emphysema is the characteristic finding of alpha-1 antitrypsin deficiency, a destructive process severely exacerbated by smoking.
Ashley Davidoff MD – TheCommonVein.com (b11684-00cL)

Panlobular Emphysema Lower Lobes	Definition A condition characterized by destruction of the lung parenchyma affecting the entire acinus, predominantly in the lower lobes. Comment This pattern is often associated with alpha-1 antitrypsin deficiency. Schoenfeld, AJR, 2011
Upper Lobes Centrilobular Emphysema	Definition A condition characterized by destruction of the lung parenchyma affecting the central portion of the acinus, predominantly in the upper lobes. Comment This pattern is typically associated with cigarette smoking. Schoenfeld, AJR, 2011
Architectural Distortion	Definition Architectural distortion is characterized by the abnormal displacement of bronchi, vessels, fissures, or septa. Comment It is a hallmark feature of fibrotic lung diseases and is usually associated with pulmonary fibrosis and volume loss. Hansell, Radiology 2008
Bronchial Wall Thickening	Definition An increase in the thickness of the walls of the bronchi, often indicative of inflammation or other pathological processes. Comment Can be associated with chronic bronchitis, asthma, or infections. Schoenfeld, AJR, 2011

Lower Lobe Cystic Emphysematous Disease

Hyperinflation
Upper Lobe Emphysema
bronchial wall thickening

Enlarged Air Spaces

Definition

Focal lucency >1 cm sharply demarcated by a thin wall (≤1 mm), typically associated with adjacent emphysematous changes.

Comment

A bulla is a focal lucency >1 cm sharply demarcated by a thin wall (≤1 mm), typically associated with adjacent emphysematous changes.
Lung cancers with air lucency (LCAL) can present as cystic, cavitary, bullous, pseudocavitary, or bubble-like lesions.

Citation: 1. Hansell DM, et al. Fleischner Society: glossary on imaging of the lungs and pleura. Radiology. 2011;258(3):1001-1014.

Low Attenuation

Definition

A cyst is a lucency within normal lung parenchyma with a well-demarcated interface (of variable thickness, usually <2 mm).
A cavity is a lucency within an area of pulmonary consolidation, mass, or nodule.
Lung cancers with air lucency (LCAL) can present as cystic, cavitary, bullous, pseudocavitary, or bubble-like lesions.

Comment

LCALs can be solitary, peripheral, round, or oval cysts in the lower lobes, and are not necessarily associated with smoking or emphysema.
Benign thin-walled pulmonary cysts are common and increase slightly with age.
Most benign cysts remain stable over time, but some can increase in size.
Progression of LCAL is often rapid once a solid component appears.

Citation: 1. Hansell DM, et al. Fleischner Society: glossary on imaging of the lungs and pleura. Radiology. 2011;258(3):1001-1014.

Decrease Vascularity

Definition

Pulmonary hyperlucency can result from an excess of air in the lung parenchyma or a decrease in lung parenchyma mass due to reduced vasculature, blood flow, or airway obliteration.

Comment

A hyperlucent lung is defined as a lung with reduced markings on its chest radiograph and increased areas of transradiancy, usually associated with pulmonary emphysema.
Other causes of hyperlucency include technical factors, chest wall abnormalities, pneumothorax, pleural opacity, pulmonary agenesis or hypoplasia, and lung fibrosis.

Citation: 1. Hansell DM, et al. Fleischner Society: glossary on imaging of the lungs and pleura. Radiology. 2011;258(3):1001-1014.

Differential Diagnosis of Lower Lobe Emphysema and Cysts

Condition	Comment
Alpha-1-Antitrypsin (AAT) Deficiency	This is the classic cause of basal-predominant panlobular emphysema, resulting from a genetic deficiency of AAT protein. It should be suspected in young patients, non-smokers, or those with a suggestive family history.
Smoking-Related Emphysema	While typically causing upper-lobe centrilobular emphysema, smoking can also cause or contribute to lower-lobe predominant emphysema, which may be panlobular in appearance.
Intravenous Drug Use	The injection of talc or other particulates from crushed oral medications (e.g., Ritalin, methadone) can lead to a basilar-predominant panlobular emphysema.
Lymphocytic Interstitial Pneumonia (LIP)	Often associated with autoimmune diseases (e.g., Sjögren syndrome) or immunodeficiency (e.g., HIV), LIP can present with thin-walled, perivascular cysts, which are typically located in the lower lobes. Ground-glass opacities are also common.
Birt-Hogg-Dubé (BHD) Syndrome	A rare genetic disorder characterized by skin fibrofolliculomas, renal tumors, and pulmonary cysts. The cysts in BHD are often thin-walled, oval or lentiform in shape, and have a lower-lobe and subpleural predominance.
Desquamative Interstitial Pneumonia (DIP)	A rare smoking-related interstitial lung disease, DIP primarily manifests as extensive ground-glass opacities with a lower-lobe and peripheral predominance. Small cystic changes can be seen within the areas of ground-glass opacity in about a third of patients.

Distinguishing Features of Cystic and Lucent Lung Lesions

Finding	Key HRCT Features & Distinctions
Lung Cyst	A round, air-filled space with a well-defined, thin wall (typically <2 mm thick). Cysts are a key feature in diseases like lymphangioleiomyomatosis (LAM), pulmonary Langerhans cell histiocytosis (PLCH), Birt-Hogg-Dubé (BHD) syndrome, and lymphocytic interstitial pneumonia (LIP). Unlike emphysema, they have a discernible, complete wall.
Emphysema	Characterized by permanent enlargement of airspaces with destruction of their walls. Critically, lacks a visible, complete wall on HRCT. Centrilobular emphysema often has a “dot-like” central artery and no distinct walls. Panlobular emphysema (seen in AAT deficiency) shows uniform low attenuation across the secondary pulmonary lobule.
Lymphocytic Interstitial Pneumonia (LIP)	Features scattered, thin-walled, often perivascular cysts, typically with a lower-lobe predominance. The presence of associated ground-glass opacities, septal thickening, and a connection to autoimmune disease or immunodeficiency are key differentiating points.
Desquamative Interstitial Pneumonia (DIP)	The dominant finding is widespread ground-glass opacities with a basal and peripheral distribution. Cysts, when present, are typically small, few, and located within the areas of ground glass. It lacks the extensive fibrosis and honeycombing characteristic of usual interstitial pneumonia (UIP).
Severe Traction/Saccular Bronchiectasis	Represents irreversible, severe, sac-like bronchial dilation due to surrounding fibrosis. On HRCT, these appear as clusters of cysts (“bunch of grapes” appearance) that often have thicker walls than primary lung cysts and may contain air-fluid levels. A key feature is their continuity with the bronchial tree, which can be confirmed on multiplanar reconstructions.
Bronchiolectasis	This is the dilatation of bronchioles, smaller airways than those in bronchiectasis, typically from traction of surrounding fibrosis. When seen end-on, these appear as small cystic spaces. They are located within areas of fibrosis and often associated with other signs like ground-glass opacity and reticulation.

3. Diagnosis

Clinical Perspective

This case focuses on Alpha-1 Antitrypsin Deficiency (AATD), a genetic disorder with significant implications for lung and liver health. Key findings include emphysema in both the lower and upper lobes, thickening of the bronchial walls, and the underlying diagnosis of Alpha-1 Antitrypsin Deficiency.

Findings

Panlobular emphysema lower lobes
Upper lobes centrilobular emphysema
Bronchial wall thickening

Diagnosis

Alpha 1 antitrypsin deficiency

Details of Alpha-1 Antitrypsin Deficiency

Definition	AATD is an inherited genetic disorder characterized by diminished or absent levels of alpha-1 antitrypsin (AAT) protein in the circulation and lungs. AAT is a serine protease inhibitor synthesized in the liver and functions to protect lung tissue from proteolytic enzymes, primarily neutrophil elastase. The deficiency results from mutations in the SERPINA1 gene.
Cause	AATD is an autosomal codominant inherited disorder caused by mutations in the SERPINA1 gene. These mutations lead to a reduction in AAT production, impaired secretion of AAT from hepatocytes, or the production of a misfolded AAT protein that accumulates within hepatocytes. The most common and severe deficiency is associated with the PI*ZZ genotype.
Pathophysiology	The pathophysiology of AATD involves a dual mechanism: a loss-of-function in the lungs and a gain-of-function in the liver. In the lungs, insufficient AAT levels lead to an uninhibited activity of neutrophil elastase, resulting in the destruction of alveolar walls, leading to emphysema and COPD. In the liver, misfolded AAT protein accumulates within hepatocytes, impairing protein secretion and leading to endoplasmic reticulum stress, cellular dysfunction, inflammation, fibrosis, and ultimately cirrhosis.
Structural Result	In the lungs, the primary structural result is the destruction of alveolar architecture, leading to the formation of large air spaces and loss of lung elasticity, characteristic of emphysema. In the liver, the accumulation of misfolded AAT protein within hepatocytes results in cytoplasmic inclusions, hepatocellular damage, and eventually fibrosis and cirrhosis.
Functional Impact	The functional impact in the lungs is impaired pulmonary gas exchange due to emphysematous destruction, leading to dyspnea, reduced exercise tolerance, and chronic cough. In the liver, impaired function can range from subclinical elevations in liver enzymes to end-stage liver disease requiring transplantation.
Imaging	Plain chest radiographs and computed tomography (CT) scans evaluate for emphysema, bronchiectasis, bullae, or fibrosis in the lungs. CT scans, particularly CT densitometry, quantify the extent and distribution of emphysema. Hyperpolarized xenon gas (¹²⁹Xe) lung MRI offers measures of regional lung function. Liver imaging (ultrasound, elastography) assesses for hepatic fibrosis and cirrhosis.
Laboratory Tests	Serum AAT level measurement quantifies AAT protein concentration. Isoelectric focusing or genotyping identify specific SERPINA1 gene mutations and determine the phenotype. Pulmonary function tests (PFTs) assess lung function severity. Liver function tests and liver biopsy evaluate hepatic involvement.
Treatment	Augmentation therapy (weekly intravenous infusions of purified AAT protein) slows emphysema progression. Standard COPD management includes bronchodilators, inhaled corticosteroids, oxygen therapy, and pulmonary rehabilitation. Lung transplantation may be considered for advanced lung disease. Liver transplantation is the only curative option for liver disease. Smoking cessation and avoidance of respiratory irritants are paramount.
Prognosis	Prognosis varies depending on genotype, severity of lung and liver disease, smoking status, and treatment adherence. Smoking significantly worsens the prognosis for lung disease. With appropriate management, individuals may achieve a near-normal life expectancy. Advanced lung or liver disease can lead to a reduced lifespan.

4. Medical History and Culture

Etymology	The term “alpha-1 antitrypsin” originates from its electrophoretic mobility, being found in the alpha-1 globulin fraction of serum proteins. “Antitrypsin” denotes its function as an inhibitor of proteases, particularly trypsin. The deficiency is therefore termed “alpha-1 antitrypsin deficiency” (AATD).
AKA / Terminology	Alpha-1 AATD Alpha-1 protease inhibitor deficiency Alpha-1 related emphysema Genetic emphysema Hereditary pulmonary emphysema Inherited emphysema Genetic COPD Hereditary COPD
Historical Notes	The scientific journey of understanding Alpha-1 Antitrypsin Deficiency began in 1963 with the pioneering work of Laurell and Eriksson, who identified the deficiency in individuals with early-onset emphysema. This discovery revolutionized the understanding of emphysema pathophysiology, highlighting the crucial role of inflammation and proteolytic enzymes. Before this, the condition was largely unrecognized, and its genetic basis was unknown. Further research in the 1960s, such as Dr. Paul Gross’s work with rats and papain, elucidated the mechanism by which elastase destroys lung tissue, underscoring the importance of alpha-1 antitrypsin (AAT) in protecting the lungs. The 1970s saw the identification of numerous genetic patterns, or mutations, of the AAT gene, with over 140 identified to date, about one-third of which are associated with deficiency or dysfunction. In the 1980s, research began exploring the possibility of augmenting deficient AAT protein levels. The role of AATD in liver disease, particularly neonatal cirrhosis, was described by Dr. Harvey Sharp. Over time, it became evident that AATD affects not only the lungs but also the liver, with potential for cirrhosis and even liver failure in severe cases. Despite significant progress and the availability of augmentation therapy, AATD remains underdiagnosed, with many physicians and patients unaware of the disease. This underdiagnosis leads to delays in diagnosis and appropriate management, impacting patient outcomes.
Cultural or Practice Insights	The historical underdiagnosis of AATD has led to specific clinical practice considerations. The World Health Organization (WHO) recommends testing all patients with a diagnosis of COPD or adult-onset asthma for AATD due to overlapping symptoms. Similarly, clinicians are advised to suspect AATD in patients who develop COPD before age 45, COPD without a history of smoking or toxin exposure, COPD with a family history of the condition, or cirrhosis without another identifiable cause, especially if there’s a family history of liver disease. There is also a hypothesis that the Vikings may have contributed to the historical spread of AATD, linking the genetic condition to their migratory patterns. The genetic inheritance pattern of AATD is autosomal co-dominant, meaning that individuals with one abnormal gene copy (carriers) may also experience symptoms and are at increased risk of lung damage, especially if they smoke.
Notable Figures or Contributions	Laurell and Eriksson: Identified alpha-1 antitrypsin deficiency in 1963, marking the beginning of its scientific understanding. Dr. Paul Gross: Demonstrated that papain could induce emphysema in rats by destroying elastin, contributing to the understanding of protease-antiprotease mechanisms in lung damage. Dr. Harvey Sharp: First described liver disease in newborns associated with AATD. Jeffrey Teckman, MD: His research with the Alpha-1 Liver Initiative has focused on adult and pediatric liver disease related to AATD, leading to the discovery of potential treatments.
Quotes and/or Teaching Lines	“Although recently discovered, A1AT deficiency has affected human populations since antiquity.” “Your health care provider may suspect you of having this condition if you develop: COPD before age 45; COPD but you have never smoked or been exposed to toxins; COPD and you have a family history of the condition; Cirrhosis and no other cause can be found; Cirrhosis and you have a family history of liver disease.” “Alpha-1 antitrypsin deficiency is a genetic condition that can cause lung and liver damage. Lung symptoms are usually similar to emphysema.” “Despite the long history of alpha-1 antitrypsin deficiency, its characteristic clinical phenotype, and the availability of therapy, the disorder remains underdiagnosed.”
Poem	In serum’s stream, a protein’s plight, Alpha-1, dimmed, a fading light. From liver’s forge, a flawed design, To lungs and bile, a harsh confine. The protease dance, a wild, unchecked fray, Elastin yields, then fades away. Emphysema’s breath, a wheezing plea, Cirrhosis’ grip, relentlessly. A Viking’s whisper, ancient gene, Through ages passed, a silent scene. Discovered late, its truth unfurled, A hidden threat in life’s brief world. For in the code, a fateful twist, A guardian lost, a life hard-kissed. Yet knowledge dawns, and care takes hold, To mend the breach, a story told.
Art, Literature, Poetry, Song, Music Examples	Literature: While specific literary works directly addressing Alpha-1 Antitrypsin Deficiency are not prominently highlighted in the provided search results, the condition has been linked to discussions around “literature and medicine” in historical analyses of the disease. The potential link between AAT polymorphisms and “intense creative energy” (ICE) or mood disorders has also been explored in scientific literature, suggesting a possible connection to artistic and intellectual pursuits. Poetry: The provided search results do not contain specific examples of poetry about Alpha-1 Antitrypsin Deficiency. However, the nature of the disease, with its effects on breathing and life-altering consequences, lends itself to poetic expression, as demonstrated in the poem above. Music/Song: No direct references to songs or musical compositions specifically about Alpha-1 Antitrypsin Deficiency were found. However, the “Alpha-1 Europe Alliance” has used a campaign featuring Vikings to raise awareness, with a video depicting a Viking character who is interrupted by coughing, symbolizing the lung issues associated with the condition. This creative approach to public health messaging could be seen as a form of cultural expression related to the disease. Art: Visual representations of Alpha-1 Antitrypsin Deficiency are primarily found in medical contexts, such as chest X-rays or CT scans depicting emphysema. However, the disease’s link to potential “intense creative energy” (ICE) and mood disorders has been a subject of scientific inquiry, suggesting a possible indirect connection to artistic expression where such traits might be more prevalent. A campaign featuring Vikings also employed visual imagery to raise awareness.

5. Creative Arts

CT shows basilar predominant emphysema, often appearing as diffuse lower lobe destruction. Pan-lobular emphysema is characteristic, with enlarged airspaces and thin, attenuated bronchial walls. Look for bullae, especially in the lower lobes.

Misfolded protein, a genetic plight,

Liver and lung, not functioning right.

Elastase unchecked, lung tissue’s foe,

Emphysema’s damage, starts down below in the lower lungs.

Look-alikes include: Centrilobular emphysema, smoking-related emphysema, But of course in the Upper lobes
and Swyer-James syndrome which is not characteristicallty bilateral .

Misfolded protein, a genetic plight,

Liver and lung, not functioning right.

Elastase unchecked, parenchyma’s foe,

Emphysema’s damage, starts down below.

Things to remember include: Genetic, metabolic, basilar predominant emphysema, liver involvement. Associated with panlobular emphysema.

Treatment: Augmentation therapy and lung transplantation.

DNA.

Alpha-1 Antitrypsin Deficiency

(Verse 1 – Introduction & Category)
This song is about Alpha-1 Antitrypsin Deficiency, a metabolic and genetic disorder. It begins in the liver, where the protein AAT is synthesized, and impacts the lung parenchyma, specifically the alveoli and the interstitium, due to a lack of this protective protein.

(Verse 2 – Radiology)
CT demonstrates basilar-predominant panacinar emphysema. Findings may include bullae at the lung bases, flattening of the diaphragm, and a paradoxical redistribution of blood flow to the upper lung zones.

(Chorus – Core Mechanism)
A1AT deficiency means unopposed elastase action,
Leading to alveolar destruction and lung inflammation.
This proteolytic enzyme imbalance causes parenchymal damage.

(Verse 3 – Differential Diagnosis)
Look-alikes include asthma, chronic bronchitis, and bronchiectasis.

(Repeat Chorus)
A1AT deficiency means unopposed elastase action,
Leading to alveolar destruction and lung inflammation.
This proteolytic enzyme imbalance causes parenchymal damage.

(Outro – Key Takeaways + Treatment)
Things to remember include: genetic, emphysema, basilar predominance, and liver disease. Treatment is augmentation therapy, bronchodilators, glucocorticoids, or liver transplantation.

The Protest Against Alpha-1 Antitrypsin Deficiency

A Symbolic Battle Against a Genetic Legacy: The Fight in Alpha-1 Antitrypsin Deficiency
This powerful animation captures the profound struggle against

Panlobular_emphysema_associated_with_alpha-1_antitrypsin_deficiency_
There is diffuse destruction of lung tissue throughout the lobule as opposed to centrilobular emphysema in which the lung destruction is bronchocentric in the center of the lobule.Smoking appears to potentiate the development of panlobular emphysema in individuals with alpha-1 antitrypsin deficiency.
Courtesy Yale Rosen MD

This song is about Alpha-1 Anti-tripsin Deficiency.
It’s a metabolic disease that begins in the liver and affects the lungs. The process starts with a misfolded protein in the endoplasmic reticulum,
leading to accumulation in hepatocytes and eventual liver damage. This deficiency results in unopposed new-trowfil elastase activity in the lungs, damaging the lung tissue

6. MCQs

Part A

Question	Options
Alpha-1 antitrypsin deficiency (AATD) is primarily caused by mutations in which gene, leading to impaired production of the alpha-1 antitrypsin (AAT) protein?	a) CFTR b) SERPINA1 c) APOE d) HFE
The underlying mechanism of lung damage in AATD involves the unchecked activity of which enzyme, leading to the destruction of lung parenchyma?	a) Matrix metalloproteinase-9 (MMP-9) b) Neutrophil elastase c) Angiotensin-converting enzyme (ACE) d) Superoxide dismutase (SOD)
In a 55-year-old male presenting with dyspnea, which of the following clinical manifestations would be most suggestive of alpha-1 antitrypsin deficiency, even in the absence of a significant smoking history?	a) Recurrent pleural effusions b) Predominantly basilar emphysema on imaging c) Progressive interstitial fibrosis d) Tracheal stenosis
Which of the following liver manifestations is a known complication of alpha-1 antitrypsin deficiency, particularly in pediatric populations?	a) Hepatocellular carcinoma (HCC) b) Neonatal cholestatic jaundice c) Budd-Chiari syndrome d) Wilson’s disease
High-resolution computed tomography (HRCT) in alpha-1 antitrypsin deficiency-related emphysema typically demonstrates which pattern?	a) Centrilobular emphysema predominantly in the upper lobes b) Panlobular emphysema with a basilar predominance c) Paraseptal emphysema with subpleural blebs d) Bronchiolitis obliterans
Quantitative CT (QCT) densitometry in AATD is often used to assess disease severity and response to therapy. What specific measurement is commonly employed?	a) Mean lung density b) Airway wall thickness c) Percentage of lung volume with low attenuation (e.g., PD15) d) Tracheal cross-sectional area
While CT is crucial for assessing emphysema in AATD, what emerging imaging modality offers complementary functional information without radiation exposure?	a) Positron Emission Tomography (PET) b) Magnetic Resonance Imaging (MRI) with hyperpolarized gases (e.g., 129Xe) c) Ultrasound (US) elastography d) Single-photon emission computed tomography (SPECT)

Part B

Q1. Alpha-1 antitrypsin deficiency (AATD) is primarily caused by mutations in which gene, leading to impaired production of the alpha-1 antitrypsin (AAT) protein?
Option	Status	Explanation & Citation
A. CFTR	✗ Incorrect	Protein synthesis is primarily carried out by ribosomes.
B. SERPINA1	✓ Correct	Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder primarily caused by mutations in the SERPINA1 gene, which encodes the alpha-1 antitrypsin (AAT) protein. Alberts B, Mol Biol Cell, 2015.
C. APOE	✗ Incorrect	The APOE gene is involved in lipid metabolism and is associated with Alzheimer’s disease risk.
D. HFE	✗ Incorrect	Mutations in the HFE gene cause hereditary hemochromatosis.

Q2. The underlying mechanism of lung damage in AATD involves the unchecked activity of which enzyme, leading to the destruction of lung parenchyma?
Option	Status	Explanation & Citation
A. Matrix metalloproteinase-9 (MMP-9)	✗ Incorrect	While MMPs are involved in tissue remodeling, neutrophil elastase is the primary culprit in AATD-related emphysema.
B. Neutrophil elastase	✓ Correct	In individuals with AATD, the deficiency or dysfunction of AAT leads to unopposed activity of neutrophil elastase, an enzyme that degrades various proteins, including elastin, in the lung parenchyma. This enzymatic assault results in the characteristic emphysematous changes. Alberts B, Mol Biol Cell, 2015.
C. Angiotensin-converting enzyme (ACE)	✗ Incorrect	ACE is primarily involved in blood pressure regulation.
D. Superoxide dismutase (SOD)	✗ Incorrect	SOD is an antioxidant enzyme.

Q3. In a 55-year-old male presenting with dyspnea, which of the following clinical manifestations would be most suggestive of alpha-1 antitrypsin deficiency, even in the absence of a significant smoking history?
Option	Status	Explanation & Citation
A. Recurrent pleural effusions	✗ Incorrect	While possible, they are not a hallmark of AATD.
B. Predominantly basilar emphysema on imaging	✓ Correct	A characteristic finding in AATD-related emphysema, particularly in severe genotypes like PiZZ, is a basilar predominance of emphysematous changes on imaging. This contrasts with smoking-related emphysema, which typically shows upper lobe and centrilobular distribution. Dyspnea is a common presenting symptom. Alberts B, Mol Biol Cell, 2015.
C. Progressive interstitial fibrosis	✗ Incorrect	AATD primarily causes emphysema, not interstitial fibrosis.
D. Tracheal stenosis	✗ Incorrect	This is not a typical manifestation of AATD.

Q4. Which of the following liver manifestations is a known complication of alpha-1 antitrypsin deficiency, particularly in pediatric populations?
Option	Status	Explanation & Citation
A. Hepatocellular carcinoma (HCC)	✗ Incorrect	While cirrhosis is a risk factor for HCC, neonatal jaundice is a more direct and common early liver manifestation in AATD.
B. Neonatal cholestatic jaundice	✓ Correct	Liver disease is a significant manifestation of AATD. In newborns and children, AATD can lead to early-onset and prolonged cholestatic jaundice, hepatomegaly, and even liver failure. The abnormal accumulation of AAT protein within hepatocytes is implicated in the pathogenesis of liver damage. Alberts B, Mol Biol Cell, 2015.
C. Budd-Chiari syndrome	✗ Incorrect	This is a hepatic venous outflow obstruction, not a primary manifestation of AATD.
D. Wilson’s disease	✗ Incorrect	This is a genetic disorder of copper metabolism.

Q5. High-resolution computed tomography (HRCT) in alpha-1 antitrypsin deficiency-related emphysema typically demonstrates which pattern?
Option	Status	Explanation & Citation
A. Centrilobular emphysema predominantly in the upper lobes	✗ Incorrect	This pattern is more characteristic of smoking-induced emphysema.
B. Panlobular emphysema with a basilar predominance	✓ Correct	AATD most commonly leads to panlobular emphysema, characterized by uniform destruction of air spaces throughout the acinus. This pattern often shows a predilection for the lower lung zones (basilar predominance), which is a key distinguishing feature from smoking-related emphysema. Alberts B, Mol Biol Cell, 2015.
C. Paraseptal emphysema with subpleural blebs	✗ Incorrect	While blebs can occur, paraseptal emphysema is not the primary pattern.
D. Bronchiolitis obliterans	✗ Incorrect	This is a distinct inflammatory condition of the small airways.

Q6. Quantitative CT (QCT) densitometry in AATD is often used to assess disease severity and response to therapy. What specific measurement is commonly employed?
Option	Status	Explanation & Citation
A. Mean lung density	✗ Incorrect	While related, specific low-attenuation thresholds are more precise for emphysema quantification.
B. Airway wall thickness	✗ Incorrect	This parameter is more relevant for assessing airway disease like chronic bronchitis.
C. Percentage of lung volume with low attenuation (e.g., PD15)	✓ Correct	Quantitative CT (QCT) densitometry, particularly metrics like the percentage of lung volume with attenuation values below a certain threshold (e.g., 15 Hounsfield Units, often referred to as PD15), is a sensitive measure for quantifying emphysema extent and has been used to evaluate the efficacy of AAT augmentation therapy. Alberts B, Mol Biol Cell, 2015.
D. Tracheal cross-sectional area	✗ Incorrect	This is unrelated to emphysema assessment.

Q7. While CT is crucial for assessing emphysema in AATD, what emerging imaging modality offers complementary functional information without radiation exposure?
Option	Status	Explanation & Citation
A. Positron Emission Tomography (PET)	✗ Incorrect	PET is primarily used for metabolic assessment and oncology, not typically for characterizing emphysema morphology or function in AATD.
B. Magnetic Resonance Imaging (MRI) with hyperpolarized gases (e.g., 129Xe)	✓ Correct	Hyperpolarized gas (e.g., 129Xe) MRI is an advanced imaging technique that provides detailed, regional functional information about lung ventilation and gas exchange without ionizing radiation. It is emerging as a valuable complement to CT in the assessment of lung diseases like AATD. Alberts B, Mol Biol Cell, 2015.
C. Ultrasound (US) elastography	✗ Incorrect	Liver ultrasound elastography can assess liver fibrosis in AATD, but lung US is limited for evaluating emphysema.
D. Single-photon emission computed tomography (SPECT)	✗ Incorrect	SPECT is used for perfusion imaging, which can be useful but lacks the detailed regional ventilation and diffusion information provided by hyperpolarized gas MRI.

Part A — Questions

Question	Choices
Q1. The pathogenic polymerization of the Z-variant alpha-1 antitrypsin protein, a key step in the pathophysiology of both liver and lung disease, is best described by which molecular process?	1 ☐ Amyloid fibril formation via beta-pleated sheet stacking 2 ☐ Loop-sheet polymerization 3 ☐ Disulfide bond cross-linking between adjacent mutant proteins 4 ☐ Glycosylation errors leading to aggregation in the Golgi apparatus
Q2. The intracellular accumulation of Z-AAT polymers in hepatocytes triggers a specific cellular stress pathway that is crucial in mediating liver injury. What is this pathway?	1 ☐ The JAK-STAT signaling pathway 2 ☐ The extrinsic apoptosis pathway (Fas-FasL) 3 ☐ The unfolded protein response (UPR) 4 ☐ The mTOR-dependent autophagy pathway
Q3. A 58-year-old male with COPD is hospitalized for pneumonia. An incidental alpha-1 antitrypsin (AAT) level is 115 mg/dL (normal range 90-200 mg/dL). What is the most appropriate next step regarding AATD testing?	1 ☐ Reassure the patient that the level is normal and no further testing is needed 2 ☐ Proceed directly to SERPINA1 genotyping 3 ☐ Repeat the serum AAT level after the patient has recovered and is at clinical baseline 4 ☐ Order isoelectric focusing (phenotyping) as the definitive test
Q4. The landmark RAPID clinical trial demonstrated that intravenous AAT augmentation therapy has a disease-modifying effect by slowing emphysema progression. What was the primary endpoint used to prove this effect?	1 ☐ Improvement in the 6-minute walk test distance 2 ☐ Reduction in the annual rate of FEV1 decline 3 ☐ Decrease in the frequency of severe exacerbations 4 ☐ Slowing of the rate of decline in CT lung density
Q5. In addition to basal panlobular emphysema, which airway abnormality is frequently identified on chest CT in patients with severe AATD and is considered an integral part of the disease’s pulmonary manifestation?	1 ☐ Tracheobronchomegaly (Mounier-Kuhn syndrome) 2 ☐ Cylindrical bronchiectasis 3 ☐ Relapsing polychondritis with cartilage calcification 4 ☐ Diffuse idiopathic skeletal hyperostosis (DISH)
Q6. For tracking emphysema progression in AATD clinical trials, which quantitative CT (QCT) metric has been shown to be the most sensitive and widely accepted?	1 ☐ The 15th percentile of the lung density histogram (PD15) 2 ☐ Total lung capacity calculated from the CT scan 3 ☐ The ratio of functional residual capacity to total lung capacity 4 ☐ Mean lung density (MLD) across the entire lung
Q7. In a PiZZ patient with suspected liver fibrosis, which non-invasive imaging technique is considered most accurate for quantitatively assessing liver stiffness, thereby staging the degree of fibrosis?	1 ☐ Contrast-enhanced multiphase CT 2 ☐ Hepatobiliary iminodiacetic acid (HIDA) scan 3 ☐ Magnetic Resonance Elastography (MRE) 4 ☐ Technetium-99m sulfur colloid liver-spleen scan

Part B — Answers & Explanations

Question	Answer	Explanation
Q1. The pathogenic polymerization of the Z-variant alpha-1 antitrypsin protein, a key step in the pathophysiology of both liver and lung disease, is best described by which molecular process?	2 — Loop-sheet polymerization	The Z mutation allows the reactive center loop of one AAT molecule to insert into the main β-sheet (sheet A) of another, initiating a chain reaction. This specific “loop-sheet” mechanism is the defining conformational change that leads to polymer formation. Dafforn, J Biol Chem 1999
	1 — Amyloid fibril formation via beta-pleated sheet stacking	While it involves protein aggregation, the structure is distinct from the cross-beta sheet configuration characteristic of amyloid diseases like Alzheimer’s.
	3 — Disulfide bond cross-linking between adjacent mutant proteins	The polymerization is a non-covalent conformational interaction, not a process driven by the formation of disulfide bonds.
	4 — Glycosylation errors leading to aggregation in the Golgi apparatus	The primary defect is protein misfolding in the endoplasmic reticulum due to the amino acid sequence change, not a glycosylation error.
Q2. The intracellular accumulation of Z-AAT polymers in hepatocytes triggers a specific cellular stress pathway that is crucial in mediating liver injury. What is this pathway?	3 — The unfolded protein response (UPR)	Retention of misfolded Z-AAT in the endoplasmic reticulum (ER) leads to ER stress. This activates the UPR, a protective mechanism that, when chronically stimulated, can trigger pro-inflammatory and pro-apoptotic signals, leading to liver cell death.
	1 — The JAK-STAT signaling pathway	This pathway is primarily involved in cytokine signaling and immune response, not the direct response to misfolded protein accumulation.
	2 — The extrinsic apoptosis pathway (Fas-FasL)	While apoptosis is the eventual outcome, the intrinsic pathways initiated by the UPR are the primary drivers, not the extrinsic ligand-based pathway.
	4 — The mTOR-dependent autophagy pathway	Autophagy is a mechanism for degrading the polymers, but it can become overwhelmed; the UPR is the stress-sensing pathway that is triggered by the accumulation itself.
Q3. A 58-year-old male with COPD is hospitalized for pneumonia. An incidental alpha-1 antitrypsin (AAT) level is 115 mg/dL (normal range 90-200 mg/dL). What is the most appropriate next step regarding AATD testing?	3 — Repeat the serum AAT level after the patient has recovered and is at clinical baseline	AAT is an acute-phase reactant, meaning its levels increase during inflammation or infection. A “normal” level during an acute illness like pneumonia can mask an underlying deficiency; re-testing at a clinical baseline is essential for an accurate assessment.
	1 — Reassure the patient that the level is normal and no further testing is needed	This is incorrect because the acute inflammatory state may be falsely elevating the AAT level into the normal range.
	2 — Proceed directly to SERPINA1 genotyping	Genotyping is appropriate if the initial screening level is low or if there is high clinical suspicion, but the first step should be to obtain a reliable screening level.
	4 — Order isoelectric focusing (phenotyping) as the definitive test	Phenotyping is a confirmatory test, not the appropriate next step after an equivocal screening test during an acute illness.
Q4. The landmark RAPID clinical trial demonstrated that intravenous AAT augmentation therapy has a disease-modifying effect by slowing emphysema progression. What was the primary endpoint used to prove this effect?	4 — Slowing of the rate of decline in CT lung density	The RAPID trial was pivotal because it used quantitative CT lung density as the primary endpoint. It showed a statistically significant slowing of lung tissue loss in the treatment group compared to placebo, an effect not consistently seen with FEV1.
	1 — Improvement in the 6-minute walk test distance	While important for functional status, this was not the primary endpoint for demonstrating disease modification.
	2 — Reduction in the annual rate of FEV1 decline	Spirometry (FEV1) has shown high variability and was not sensitive enough to be the primary endpoint in this trial, though trends favoured the treatment group.
	3 — Decrease in the frequency of severe exacerbations	Exacerbation frequency was a secondary endpoint and, while numerically lower in the treatment group, did not reach statistical significance in the primary trial.
Q5. In addition to basal panlobular emphysema, which airway abnormality is frequently identified on chest CT in patients with severe AATD and is considered an integral part of the disease’s pulmonary manifestation?	2 — Cylindrical bronchiectasis	Bronchiectasis is a common co-morbidity, found in over 25-40% of patients with severe AATD in various studies. It is considered part of the “airway-predominant” phenotype of AATD and contributes significantly to symptoms and exacerbations.
	1 — Tracheobronchomegaly (Mounier-Kuhn syndrome)	This is a rare condition of marked tracheobronchial dilation and is not a characteristic feature of AATD.
	3 — Relapsing polychondritis with cartilage calcification	This is a systemic autoimmune disease affecting cartilage and is a distinct clinical entity.
	4 — Diffuse idiopathic skeletal hyperostosis (DISH)	This is a systemic condition of ligamentous calcification and is unrelated to AATD.
Q6. For tracking emphysema progression in AATD clinical trials, which quantitative CT (QCT) metric has been shown to be the most sensitive and widely accepted?	1 — The 15th percentile of the lung density histogram (PD15)	PD15 represents the Hounsfield unit value below which 15% of the lung voxels lie. It has been shown to be more sensitive and reproducible for detecting changes in emphysema over time compared to other metrics, and it was the key endpoint in major augmentation therapy trials.
	2 — Total lung capacity calculated from the CT scan	While CT can measure lung volume, this metric reflects hyperinflation and is less sensitive to parenchymal destruction than densitometry.
	3 — The ratio of functional residual capacity to total lung capacity	This is a physiologic measure of air trapping, typically measured by PFTs, not a primary QCT metric for emphysema.
	4 — Mean lung density (MLD) across the entire lung	MLD is less sensitive than percentile density because it can be affected by areas of fibrosis or atelectasis, which would falsely elevate the average density.
Q7. In a PiZZ patient with suspected liver fibrosis, which non-invasive imaging technique is considered most accurate for quantitatively assessing liver stiffness, thereby staging the degree of fibrosis?	3 — Magnetic Resonance Elastography (MRE)	MRE uses MRI to visualize and measure the speed of shear waves propagating through the liver, which directly correlates with tissue stiffness. It is more accurate than ultrasound-based methods, especially in obese patients, and is the most robust non-invasive tool for staging liver fibrosis.
	1 — Contrast-enhanced multiphase CT	CT can show morphologic signs of advanced cirrhosis (e.g., surface nodularity, varices) but cannot reliably stage the degree of early or intermediate fibrosis.
	2 — Hepatobiliary iminodiacetic acid (HIDA) scan	This is a nuclear medicine test that assesses hepatocyte function and bile flow, not liver fibrosis.
	4 — Technetium-99m sulfur colloid liver-spleen scan	This nuclear medicine scan can suggest cirrhosis by showing colloid shift to the spleen and bone marrow but does not quantitatively stage fibrosis.

Additional Information
see below

7. Memory Page

One Man Protest
Against His Genetic Inheritance
Panlobular Emphysema and
HCC from Cirrhosis

The Body’s Protest

He holds a banner to the sky,
A tangled truth for passersby.
A protest strange, a coded plea,
For a missing shield he cannot see.

Upon his frame, the image glows,
The story that his body shows.
The basal lungs, a faded lace,
Where breath is lost in empty space.

Below, a liver, scarred and dense,
A losing fight, a grim defense.
A knotted map, a toxic ground,
Where a dark and fatal growth is found.

The Common Vein

VG Med WF lungs lower lobes panlobular emphysema lower lobes and upper lobes centrilobular emphysema bronchial wall thickening alpha 1 antitrypsin deficiency CT 55 year old male dyspnea

1. Challenge

Ashley Davidoff MD

50M Smoker Dyspnea

5 Major Findings

2. Findings

Panlobular Emphysema Lower Lobes

Upper Lobes Centrilobular Emphysema

Architectural Distortion

Bronchial Wall Thickening

Lower Lobe Cystic Emphysematous Disease

Hyperinflation
Upper Lobe Emphysema
bronchial wall thickening

Differential Diagnosis of Lower Lobe Emphysema and Cysts

Distinguishing Features of Cystic and Lucent Lung Lesions

3. Diagnosis

Clinical Perspective

Findings

Diagnosis

Details of Alpha-1 Antitrypsin Deficiency

4. Medical History and Culture

5. Creative Arts

6. MCQs

Part A

Part B

Part A — Questions

Part B — Answers & Explanations

7. Memory Page

One Man Protest
Against His Genetic Inheritance
Panlobular Emphysema and
HCC from Cirrhosis

The Body’s Protest

Emotionally Shedding The Curse of His Genetic Inheritance of
Alpha 1 Antitrypsin Deficiency

1. Challenge

2. Findings

2. Findings

3. Diagnosis

4. Medical History and Culture

5. Creative Arts

6. MCQs

7. Memory Page

TCV

1. Challenge

Ashley Davidoff MD

50M Smoker Dyspnea

5 Major Findings

Related Links

2. Findings

Panlobular Emphysema Lower Lobes

Upper Lobes Centrilobular Emphysema

Architectural Distortion

Bronchial Wall Thickening

Lower Lobe Cystic Emphysematous Disease

HyperinflationUpper Lobe Emphysemabronchial wall thickening

Differential Diagnosis of Lower Lobe Emphysema and Cysts

Distinguishing Features of Cystic and Lucent Lung Lesions

Related Links

3. Diagnosis

Clinical Perspective

Findings

Diagnosis

Details of Alpha-1 Antitrypsin Deficiency

Related Links

4. Medical History and Culture

Related Links

5. Creative Arts

Related Links

6. MCQs

Part A

Part B

Part A — Questions

Part B — Answers & Explanations

Related Links

7. Memory Page

One Man Protest Against His Genetic InheritancePanlobular Emphysema and HCC from Cirrhosis

The Body’s Protest

Emotionally Shedding The Curse of His Genetic Inheritance of Alpha 1 Antitrypsin Deficiency

Related Links

1. Challenge

2. Findings

2. Findings

3. Diagnosis

4. Medical History and Culture

5. Creative Arts

6. MCQs

7. Memory Page

TCV

Hyperinflation
Upper Lobe Emphysema
bronchial wall thickening

One Man Protest
Against His Genetic Inheritance
Panlobular Emphysema and
HCC from Cirrhosis

Emotionally Shedding The Curse of His Genetic Inheritance of
Alpha 1 Antitrypsin Deficiency